Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Corixa Bexxar User Fee Deadline Extended To Review Safety Database

Executive Summary

FDA is extending GSK/Corixa's Bexxar user fee deadline by three months to review additional safety information on the radioimmunotherapy
Advertisement

Related Content

GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
GSK/Corixa Bexxar Nuclear Pharmacy Training Kicks Off With FDA Approval
Erbitux BLA Resubmission Plan Set; Will Test Accelerated Approval Rules
Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street
Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street
Drug Manufacturer Education Grants To Purchasers May Be Kickback, IG Says
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Corixa/GSK Will Submit Bexxar-Zevalin Trial Protocol To FDA In January
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Idec Zevalin NHL Indication Split By Accelerated/Standard Approval
Advertisement
UsernamePublicRestriction

Register

PS041778

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel